Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-14.5% vs SMA 50 · -15.4% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $40000 $40000–$40000 | — | -$0.64 | — | ±2% | Moderate4 |
FY2026(current) | $50000 $50000–$50000 | ▲ +25.0% | -$0.61 | — | ±7% | Moderate4 |
FY2027 | $225000 $225000–$225000 | ▲ +350.0% | -$0.64 | — | ±22% | Moderate4 |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,…
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.